1083P KEYMAKER 02B: A randomized trial of pembrolizumab (pembro) alone or with investigational agents as first-line treatment for advanced melanoma.
Saved in:
| Title: | 1083P KEYMAKER 02B: A randomized trial of pembrolizumab (pembro) alone or with investigational agents as first-line treatment for advanced melanoma. |
|---|---|
| Authors: | Dummer, R.1 (AUTHOR), Shapira, R.2 (AUTHOR), Pigozzo, J.3 (AUTHOR), Ascierto, P.A.4 (AUTHOR), Gaudy Marqueste, C.5 (AUTHOR), Portnoy, D.6 (AUTHOR), Del Vecchio, M.7 (AUTHOR), Bar-Sela, G.8 (AUTHOR), Cohen, J.E.9 (AUTHOR), Di Giacomo, A.M.10 (AUTHOR), Ribas, A.11 (AUTHOR), Dutriaux, C.12 (AUTHOR), Belli, C.13 (AUTHOR), Cohen, G.14 (AUTHOR), Dokhan, R.15 (AUTHOR), Jing, N.16 (AUTHOR), Lal, R.17 (AUTHOR), Krepler, C.18 (AUTHOR), Long, G.V.19 (AUTHOR) |
| Source: | Annals of Oncology. 2024 Supplement 2, Vol. 35, pS717-S718. 2p. |
| Database: | Academic Search Ultimate |
| ISSN: | 09237534 |
|---|---|
| DOI: | 10.1016/j.annonc.2024.08.1151 |
